mTOR inhibitors vs chemotherapy/hormone therapy
Progression‐free survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer
mTOR inhibitors probably leads to lower progression‐free survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (moderate certainty).
1 finding from 1 review
- PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes onlyHR 0.53 [0.31, 0.91]1 study · 95 participantsModerate